Recently, RNA editing of MeCP2 expression levels in the brainstem has been shown to alleviate symptoms in a mouse model of RTT [128] and epigenome editing was used to reactivate silenced MECP2 on the inactive X chromosome in RTT-derived stem cells and neurons [129]. The gene discussed is MECP2; the disease is Rett syndrome.